Topics:
Lung Cancer • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Yale • NCI-CCC Thoracic Tumor Board Question
Would you offer adjuvant TKI to patients with Stage III, EGFR-mutant NSCLC after standard chemoradiation?
Would you offer adjuvant TKI following ADAURA data? Or proceed with durvalumab based on PACIFIC data?
Answer from: Medical Oncologist at Academic Institution
I would definitely not use adjuvant erlotinib after either surgery or radiation at the current time. The data do not support this, and it is has significant toxicity. Not statistically significant means that the data are likely to have come out this way by chance. The disease free...
Sign in or Register to read more